Sinopharm CNBG COVID-19 vaccine

Sinopharm CNBG COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of; administration	Intramuscular
Legal status
Legal status	Full list of Sinopharm NVSI authorizations;
Identifiers
CAS Number	2503126-65-4;

Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.^[2]^[3]

They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).^[4] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.^[5]

References

^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
^ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
^ 國藥集團：二代重組蛋白新冠疫苗保護效果良好
^ Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022). "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812.

Scholia has a profile for Sinopharm CNBG COVID-19 vaccine (Q110291641).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

[1] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[2] "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.

[3] "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.

[4] 國藥集團：二代重組蛋白新冠疫苗保護效果良好

[5] Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022). "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812.

[1]

[2]

[3]

[4]

[5]